

Marco Vignetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7792955/publications.pdf>

Version: 2024-02-01

142
papers

10,703
citations

50170

46
h-index

31759

101
g-index

143
all docs

143
docs citations

143
times ranked

10081
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e344-e351.	0.8	1
2	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753.	2.5	33
3	ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. <i>Blood Advances</i> , 2022, 6, 2510-2516.	2.5	3
4	Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. <i>Frontiers in Oncology</i> , 2022, 12, 826040.	1.3	5
5	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e328-e333.	0.2	0
6	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	0.6	10
7	Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric GIMEMA LAL1308 trial. <i>American Journal of Hematology</i> , 2021, 96, 292-301.	2.0	21
8	A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. <i>Haematologica</i> , 2021, 106, 1828-1838.	1.7	33
9	Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis. <i>Value in Health</i> , 2021, 24, 250-267.	0.1	63
10	Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. <i>British Journal of Haematology</i> , 2021, 193, 386-396.	1.2	23
11	Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Expert Review of Hematology</i> , 2021, 14, 293-302.	1.0	5
12	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	0.8	8
13	The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study. <i>JMIR Research Protocols</i> , 2021, 10, e25271.	0.5	4
14	Prognostic impact of KMT2A-AFF1 positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. <i>American Journal of Hematology</i> , 2021, 96, E334-E338.	2.0	3
15	Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. <i>Blood</i> , 2021, 138, 2290-2293.	0.6	15
16	Health-related quality of life in patients with acute promyelocytic leukemia: a systematic literature review. <i>Expert Review of Hematology</i> , 2021, 14, 645-654.	1.0	1
17	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. <i>Blood</i> , 2021, 138, 2727-2730.	0.6	9
18	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 31-44.	2.4	11

#	ARTICLE	IF	CITATIONS
19	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379.	2.5	5
20	AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance – AMYNERVA-GIMEMA AML1919 trial. <i>Future Oncology</i> , 2021, 17, 3787-3796.	1.1	0
21	Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey. <i>Blood Advances</i> , 2021, 5, 5608-5611.	2.5	11
22	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	3.3	46
23	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. <i>Leukemia</i> , 2020, 34, 488-498.	3.3	35
24	Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies. <i>Quality of Life Research</i> , 2020, 29, 815-823.	1.5	12
25	Dasatinib + Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. <i>New England Journal of Medicine</i> , 2020, 383, 1613-1623.	13.9	279
26	Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials. <i>Cancers</i> , 2020, 12, 3334.	1.7	6
27	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	1.3	12
28	COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. <i>Leukemia</i> , 2020, 34, 2813-2814.	3.3	16
29	Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies. <i>Journal of Clinical Epidemiology</i> , 2020, 127, 9-18.	2.4	10
30	Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning. <i>British Journal of Haematology</i> , 2020, 190, e304-e307.	1.2	1
31	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020, 34, 2451-2459.	3.3	14
32	Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study. <i>American Journal of Hematology</i> , 2020, 95, 749-758.	2.0	12
33	Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2020-002281.	0.8	1
34	Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol. <i>Leukemia and Lymphoma</i> , 2019, 60, 3482-3492.	0.6	3
35	Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. <i>Value in Health</i> , 2019, 22, 1303-1310.	0.1	18
36	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019, 134, 935-945.	0.6	148

#	ARTICLE	IF	CITATIONS
37	Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusionâ€dependent patients with myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2019, 102, 442-443.	1.1	1
38	IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies. <i>Leukemia and Lymphoma</i> , 2019, 60, 829-832.	0.6	10
39	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 312-318.	1.7	54
40	Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia. <i>Leukemia</i> , 2019, 33, 1598-1607.	3.3	15
41	Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2018, 59, 2715-2718.	0.6	2
42	Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. <i>Cancer</i> , 2018, 124, 2228-2237.	2.0	22
43	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
44	Rapid identification of BCR/ABL¹-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real timeâ€polymerase chain reaction: clinical, prognostic and therapeutic implications. <i>British Journal of Haematology</i> , 2018, 181, 642-652.	1.2	46
45	Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. <i>Cancer</i> , 2018, 124, 1251-1259.	2.0	31
46	TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. <i>Blood</i> , 2018, 132, 3119-3119.	0.6	1
47	Low-dose clofarabine in combination with a standard remission induction in patients aged 18â€60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial. <i>Haematologica</i> , 2017, 102, e47-e51.	1.7	5
48	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Nonâ€High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 605-612.	0.8	299
49	Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase II GIMEMA trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 1640-1647.	0.6	8
50	Physiciansâ€™ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 204.	1.0	0
51	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. <i>Oncotarget</i> , 2016, 7, 13886-13901.	0.8	20
52	A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. <i>Haematologica</i> , 2016, 101, 1544-1552.	1.7	72
53	Unbiased pro-thrombotic features at diagnosis in 977 thrombocytopenic patients with Philadelphia-negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2016, 46, 18-25.	0.4	13
54	RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. <i>Haematologica</i> , 2016, 101, 941-950.	1.7	44

#	ARTICLE	IF	CITATIONS
55	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. <i>Leukemia Research</i> , 2016, 41, 36-42.	0.4	41
56	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 972-979.	0.8	296
57	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. <i>Blood</i> , 2016, 128, 2038-2038.	0.6	3
58	Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. <i>Annals of Hematology</i> , 2015, 94, 23-34.	0.8	12
59	Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 542-554.	2.0	35
60	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2015, 16, 1506-1514.	5.1	76
61	Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification. <i>Blood</i> , 2015, 126, 81-81.	0.6	44
62	Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. <i>Haematologica</i> , 2014, 99, 788-793.	1.7	85
63	Treatment of Philadelphia-positive acute lymphoid leukemia. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 71-83.	0.7	0
64	Deferasirox for transfusionâ€dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (<sc>GIMEMA MDS</sc>0306 <sc>T</sc>rial). <i>European Journal of Haematology</i> , 2014, 92, 527-536.	1.1	90
65	Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 3406-3412.	0.8	76
66	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014, 38, 198-203.	0.4	4
67	High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 219-228.	0.8	145
68	<i>NOTCH1, SF3B1, BIRC3</i>and<i>TP53</i>mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. <i>Leukemia and Lymphoma</i> , 2014, 55, 2785-2792.	0.6	47
69	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	13.9	1,284
70	Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic review. <i>Leukemia Research</i> , 2013, 37, 206-213.	0.4	37
71	Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17). <i>Journal of Clinical Oncology</i> , 2013, 31, 4424-4430.	0.8	78
72	Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials. <i>Blood</i> , 2013, 122, 829-829.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?. <i>Annals of Hematology</i> , 2012, 91, 1371-1381.	0.8	51
74	IKAROS Deletions Dictate a Unique Gene Expression Signature in Patients with Adult B-Cell Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2012, 7, e40934.	1.1	73
75	Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. <i>Annals of Hematology</i> , 2012, 91, 825-835.	0.8	19
76	Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML1107). <i>British Journal of Haematology</i> , 2012, 156, 205-212.	1.2	65
77	Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. <i>Blood</i> , 2011, 118, 4554-4560.	0.6	221
78	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 6521-6528.	0.6	395
79	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. <i>Blood</i> , 2011, 117, 4716-4725.	0.6	173
80	GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. <i>British Journal of Haematology</i> , 2011, 154, 564-568.	1.2	22
81	Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the <i>MLL/ENL</i> fusion gene. <i>American Journal of Hematology</i> , 2011, 86, 993-997.	2.0	4
82	A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2011, 35, 1052-1059.	0.4	74
83	A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. <i>Leukemia and Lymphoma</i> , 2011, 52, 2329-2335.	0.6	7
84	<i>CDKN2A/B</i> Alterations Impair Prognosis in Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia Patients. <i>Clinical Cancer Research</i> , 2011, 17, 7413-7423.	3.2	62
85	Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. <i>Haematologica</i> , 2011, 96, 552-557.	1.7	84
86	International Development of An EORTC Measure to Assess Patient-Reported Quality of Life (QoL) and Symptoms in Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2011, 118, 3132-3132.	0.6	4
87	Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). <i>Blood</i> , 2010, 115, 3776-3786.	0.6	109
88	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010, 116, 3171-3179.	0.6	290
89	Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological study. <i>British Journal of Haematology</i> , 2010, 149, 70-78.	1.2	9
90	Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML119). <i>British Journal of Haematology</i> , 2010, 149, 376-382.	1.2	52

#	ARTICLE	IF	CITATIONS
91	The therapeutic response and clinical outcome of adults with ALL1 (MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience. <i>Haematologica</i> , 2010, 95, 837-840.	1.7	12
92	The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. <i>Haematologica</i> , 2010, 95, 1683-1690.	1.7	51
93	GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials. <i>Blood</i> , 2010, 116, 871-871.	0.6	7
94	The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients. <i>Blood</i> , 2010, 116, 3136-3136.	0.6	0
95	Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2009, 94, 102-112.	1.7	23
96	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2009, 15, 5002-5007.	3.2	103
97	D Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10. <i>Journal of Clinical Oncology</i> , 2009, 27, 5397-5403.	0.8	180
98	Asking patients with hematological malignancies: "how do you feel?" Does it really provide independent prognostic information for survival?. <i>European Journal of Haematology</i> , 2009, 82, 484-485.	1.1	3
99	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). <i>Blood</i> , 2009, 114, 2159-2167.	0.6	201
100	IKZF1 (Ikaros) Deletions in BCR-ABL1-Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 5202-5207.	0.8	276
101	Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1803-1808.	0.6	11
102	Response: NPM1-mutated AML is an entity irrespective of whether or not chromosomal aberrations are present. <i>Blood</i> , 2009, 114, 4602-4603.	0.6	3
103	AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. <i>Blood</i> , 2009, 114, 3024-3032.	0.6	156
104	Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL): An Update of the GIMEMA Experience.. <i>Blood</i> , 2009, 114, 3097-3097.	0.6	3
105	BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.. <i>Blood</i> , 2009, 114, 648-648.	0.6	6
106	Value of Low Dose IL-2 as Maintenance Following Consolidation Treatment or Autologous Transplantation in Acute Myelogenous Leukemia (AML) Patients Aged 15-60 Years Who Reached CR After High Dose (HD-AraC) Vs Standard Dose (SD-AraC) Cytosine Arabinoside During Induction: Results of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups.. <i>Blood</i> , 2009, 114, 791-791.	0.6	11
107	Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).. <i>Blood</i> , 2009, 114, 1777-1777.	0.6	0
108	IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.. <i>Blood</i> , 2009, 114, 912-912.	0.6	0

#	ARTICLE	IF	CITATIONS
109	PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.. <i>Blood</i> , 2009, 114, 12-12.	0.6	2
110	Liposomal daunorubicin <i>versus</i> standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AML randomized trial in patients older than 60 years with acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 2008, 143, 681-689.	1.2	54
111	Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials â€” A systematic review to evaluate the added value in supporting clinical decision making. <i>European Journal of Cancer</i> , 2008, 44, 1497-1506.	1.3	79
112	Somatically acquired <i>JAK1</i> mutations in adult acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2008, 205, 751-758.	4.2	318
113	Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. <i>Haematologica</i> , 2008, 93, 1814-1821.	1.7	39
114	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1017-1024.	1.7	22
115	High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SDAraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC) <i>Tj ETQq110.784314 rgBT</i>	0.6	4
116	Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party. <i>Blood</i> , 2008, 112, 722-722.	0.6	4
117	Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. <i>Haematologica</i> , 2007, 92, 342-348.	1.7	47
118	ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 5473-5476.	0.6	46
119	Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosomeâ€”positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. <i>Blood</i> , 2007, 109, 3676-3678.	0.6	336
120	Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here?. <i>Haematologica</i> , 2007, 92, 1596-1598.	1.7	38
121	Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61 70 years: results of the prospective EORTC GIMEMA AML 13 study. <i>Haematologica</i> , 2007, 92, 389-396.	1.7	48
122	Dasatinib as Front-Line Monotherapy for the Induction Treatment of Adult and Elderly Ph+ Acute Lymphoblastic Leukemia (ALL) Patients: Interim Analysis of the GIMEMA Prospective Study LAL1205.. <i>Blood</i> , 2007, 110, 7-7.	0.6	16
123	Protein Expression of p15 and p21 Plays an Unfavorable Prognostic Role in Adult Acute Lymphoblastic Leukemia (ALL) Patients Independently of Their Gene Promoter Methylation Status.. <i>Blood</i> , 2007, 110, 2802-2802.	0.6	2
124	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. <i>Blood</i> , 2006, 107, 473-479.	0.6	109
125	Protein Expression and Methylation Status of the CKI p21, p15 and p16 in Adult Acute Lymphoblastic Leukemia (ALL) Patients: Prognostic Implications.. <i>Blood</i> , 2006, 108, 1843-1843.	0.6	0
126	GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. <i>Blood</i> , 2005, 106, 447-453.	0.6	196

#	ARTICLE	IF	CITATIONS
127	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. <i>Blood</i> , 2005, 105, 3434-3441.	0.6	178
128	Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. <i>Blood</i> , 2005, 106, 27-34.	0.6	146
129	Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype. <i>New England Journal of Medicine</i> , 2005, 352, 254-266.	13.9	1,637
130	A New Method To Evaluate the Prognostic Value of Response to Prednisone Pre-Treatment in Adult (15-60 Yrs) Patients with Acute Lymphoblastic Leukemia: Results of the GIMEMA LAL 2000 Study.. <i>Blood</i> , 2005, 106, 1829-1829.	0.6	3
131	Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. <i>Blood</i> , 2005, 106, 1098-1098.	0.6	4
132	Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. <i>Blood</i> , 2004, 103, 2771-2778.	0.6	296
133	Dramatic Improvement in CR Rate and CR Duration with Imatinib in Adult and Elderly Ph+ ALL Patients: Results of the GIMEMA Prospective Study LAL0201.. <i>Blood</i> , 2004, 104, 2739-2739.	0.6	10
134	Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group.. <i>Blood</i> , 2004, 104, 392-392.	0.6	30
135	Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. <i>Blood</i> , 2002, 100, 1972-1976.	0.6	91
136	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 974-981.	0.6	99
137	Extramedullary Involvement at Relapse in Acute Promyelocytic Leukemia Patients Treated or Not With All-Trans Retinoic Acid: A Report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. <i>Journal of Clinical Oncology</i> , 2001, 19, 4023-4028.	0.8	135
138	Use of Interleukin-2 in the Management of Haematological Malignancies. <i>BioDrugs</i> , 1999, 12, 43-53.	2.2	2
139	Interleukin-2 for the Treatment of Advanced Acute Myelogenous Leukemia Patients with Limited Disease: Updated Experience with 20 Cases. <i>Leukemia and Lymphoma</i> , 1996, 21, 429-435.	0.6	30
140	Autologous Bone Marrow Transplantation in 44 Patients with Aggressive Non-Hodgkin's Lymphoma at University of La Sapienza of Rome. <i>Leukemia and Lymphoma</i> , 1996, 23, 147-151.	0.6	1
141	Interleukin 2 treatment in acute myelogenous leukemia. <i>Stem Cells</i> , 1993, 11, 263-268.	1.4	9
142	Letter to the editor: Acute myeloid leukemia in a child affected by β^2 -thalassemia major. <i>American Journal of Hematology</i> , 1988, 29, 124-124.	2.0	4